Larimar Therapeutics, Inc. — All Filings
675 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
4
4/A
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
D/A
DEF 14A
DEFA14A
DEFM14A
DRS
DRS/A
EFFECT
PRE 14A
PREM14A
PRER14A
REGDEX
S-1
S-1/A
S-1MEF
S-3
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| S-8 | S-8 | 0001193125-26-116159 | Mar 19, 2026 | — |
| 10-K | 10-K | 0001193125-26-115878 | Mar 19, 2026 | Dec 31, 2025 |
| 8-K | 8-K | 0001193125-26-115119 | Mar 19, 2026 | — |
| 8-K | 8-K | 0001193125-26-098493 | Mar 9, 2026 | — |
| SCHEDULE 13D/A | — | 0001193805-26-000206 | Mar 2, 2026 | — |
| 4 | — | 0001193805-26-000205 | Mar 2, 2026 | Feb 27, 2026 |
| 4 | 4 | 0001193125-26-085515 | Mar 2, 2026 | Feb 27, 2026 |
| 4 | 4 | 0001193125-26-085514 | Mar 2, 2026 | Feb 27, 2026 |
| 4 | 4 | 0001193125-26-085510 | Mar 2, 2026 | Feb 27, 2026 |
| 8-K | 8-K | 0001193125-26-077646 | Feb 27, 2026 | Feb 25, 2026 |
| 424B5 | 424B5 | 0001193125-26-076775 | Feb 26, 2026 | — |
| 424B5 | 424B5 | 0001193125-26-071493 | Feb 25, 2026 | — |
| 8-K | 8-K | 0001193125-26-065186 | Feb 24, 2026 | — |
| SCHEDULE 13G/A | — | 0001346824-26-000047 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001140361-26-005033 | Feb 12, 2026 | — |
| 4 | 4 | 0001193125-26-024833 | Jan 27, 2026 | Jan 26, 2026 |
| 4 | 4 | 0001193125-26-024832 | Jan 27, 2026 | Jan 26, 2026 |
| 4 | 4 | 0001193125-26-024826 | Jan 27, 2026 | Jan 26, 2026 |
| 4 | 4 | 0001193125-26-024824 | Jan 27, 2026 | Jan 26, 2026 |
| 8-K | 8-K | 0001193125-26-018664 | Jan 22, 2026 | Jan 21, 2026 |
| 8-K | 8-K | 0001193125-26-010409 | Jan 12, 2026 | — |
| 8-K | 8-K | 0001193125-25-321738 | Dec 17, 2025 | Dec 16, 2025 |
| 8-K | 8-K | 0001193125-25-273217 | Nov 10, 2025 | — |
| SCHEDULE 13G/A | — | 0001104659-25-107757 | Nov 6, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-266969 | Nov 5, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-265702 | Nov 5, 2025 | — |
| 8-K | 8-K | 0001193125-25-237998 | Oct 14, 2025 | — |
| 8-K | 8-K | 0001193125-25-221538 | Sep 29, 2025 | — |
| SCHEDULE 13G | — | 0001641172-25-025979 | Aug 29, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-108797 | Aug 14, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0000950170-25-108409 | Aug 14, 2025 | — |
| 4 | — | 0001193805-25-001155 | Aug 4, 2025 | Jul 31, 2025 |
| SCHEDULE 13D/A | — | 0001193805-25-001138 | Jul 31, 2025 | — |
| 8-K | 8-K | 0001193125-25-169818 | Jul 31, 2025 | Jul 29, 2025 |
| 424B5 | 424B5 | 0001193125-25-169661 | Jul 31, 2025 | — |
| 8-K | 8-K | 0001193125-25-168096 | Jul 29, 2025 | — |
| 424B5 | 424B5 | 0001193125-25-168035 | Jul 29, 2025 | — |
| 8-K | 8-K | 0000950170-25-089074 | Jun 23, 2025 | — |
| 8-K | 8-K | 0000950170-25-088704 | Jun 23, 2025 | — |
| SCHEDULE 13G | — | 0001104659-25-060256 | Jun 17, 2025 | — |
| 4 | — | 0001193805-25-000672 | May 15, 2025 | May 13, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-009380 | May 14, 2025 | May 13, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-009379 | May 14, 2025 | May 13, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-009378 | May 14, 2025 | May 13, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-009377 | May 14, 2025 | May 13, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-009376 | May 14, 2025 | May 13, 2025 |
| 8-K | 8-K | 0000950170-25-070287 | May 13, 2025 | — |
| 8-K | 8-K | 0000950170-25-063125 | May 5, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-061222 | Apr 30, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0000950170-25-060563 | Apr 30, 2025 | — |